CHRONOS‐3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (INHL)
- Resource Type
- Source
- Hematological Oncology. 39
- Subject
Oncology Cancer Research medicine.medical_specialty business.industry Hematology General Medicine Placebo chemistry.chemical_compound chemistry Internal medicine Indolent Non-Hodgkin Lymphoma Medicine Rituximab business Copanlisib medicine.drug - Language
- ISSN
- 1099-1069
0278-0232